|
Serum soluble MAdCAM-1: A new biomarker for cancer immunotherapy. |
|
Carolina Alves Costa Silva |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Anne-Laure Mallard de La Varende |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Ipsen; Pfizer |
|
|
Leadership - EverImmune; Hookipa Biotech; Transgene |
Stock and Other Ownership Interests - EverImmune |
Honoraria - EverImmune; Hookipa Biotech; Transgene |
Consulting or Advisory Role - EverImmune; German Cancer Aid; Hookipa Biotech; Pierre Fabre; Transgene |
Research Funding - 9 Meters Biopharma; Biomérieux; Daiichi Sankyo; EverImmune; Pileje; Transgene |
Patents, Royalties, Other Intellectual Property - EverImmune |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca |
Other Relationship - Seerave Foundation |
(OPTIONAL) Uncompensated Relationships - MaaT Pharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Ipsen; MSD |